Of Counsel Mark Neuberger was quoted in the CNN Business article, “Stuck at Home, But Can’t Do Your Job Remotely? Here’s What to Expect.”
Many employers are having to make tough calls on the fly as the COVID-19 pandemic plays out and wreaks havoc on the economy. Some are trying to figure out if they can keep employees on the payroll or if they should furlough them with an implicit promise to bring them back when things improve. Or if they should lay them off altogether.
Furloughing can have benefits implications, Neuberger said. Depending on how a company’s health plan is written, the employer may continue subsidizing furloughed workers’ health insurance premiums, whereas that might not be allowed for laid-off workers.
Many employers are having to make tough calls on the fly as the COVID-19 pandemic plays out and wreaks havoc on the economy. Some are trying to figure out if they can keep employees on the payroll or if they should furlough them with an implicit promise to bring them back when things improve. Or if they should lay them off altogether.
Furloughing can have benefits implications, Neuberger said. Depending on how a company’s health plan is written, the employer may continue subsidizing furloughed workers’ health insurance premiums, whereas that might not be allowed for laid-off workers.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”